Kurt A. Jaeckle, M.D.

Closed for Enrollment

• A Phase III Trial Of Marizomib In Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone In Patients With Newly Diagnosed Glioblastoma MIRAGE Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

  The purpose of this study is to evaluate the safety and tolerability of marizomib in combination with Temozolomide-based radiochemotherapy versus standard Temozolomide-based radiochemotherapy alone in newly diagnosed glioblastoma patients. 

• A Randomized Phase 3 Open-Label Study To Evaluate The Efficacy And Safety Of Eflornithine With Lomustine Compared To Lomustine Alone In Patients With AA That Progress/Recur After Irradiation And Adjuvant Temozolomide Chemotherapy Jacksonville, Fla., Rochester, Minn.

  The purpose of this study is to compare the efficacy and safety of eflornithine in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has recurred/progressed after radiation and temozolomide chemotherapy.

• A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Of Enzastaurin Added To Temozolomide During And Following Radiation Therapy In Newly Diagnosed Glioblastoma Patients Who Possess The Novel Genomic Biomarker DGM1 Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

  The purpose of this study is to assess whether there is superiority of overall survival (OS) when enzastaurin rather than placebo is added to the regimen of temozolomide with radiation therapy followed by temozolomide for the treatment of patients with newly diagnosed glioblastoma in Denovo Genomic Marker 1 (DGM1) biomarker-positive patients.

• Expanded Access To ONC201 For Patients With H3 K27M-mutant And/or Midline High Grade Gliomas Jacksonville, Fla., Rochester, Minn.

  The purpose of this project is to provide expanded access to ONC201 for patients with previously-treated H3 K27M-mutant and/or midline high grade gliomas who cannot access ONC201 through clinical trials.

• Mayo CEReBral Biobank: Mayo CNS Enterprise Research Brain Biobank Jacksonville, Fla.

  The primary goal of this project is to collect human nervous system tissue, blood-derived, and cerebrospinal fluid specimens for storage.

• Study Of LY3410738 Administered To Patients With Advanced Solid Tumors With IDH1 Mutations Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with IDH1 R132-mutant advanced solid tumor types, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma.